Michael Blackton, MBA Elektrofi

A member of PDA since approximately 1996, he is currently the SVP Technical Operations at Elektrofi. Prior to joining Elektrofi, Michael had roles in Quality, Operations, and Manufacturing over a career spanning 30 years with experience in monoclonal antibodies, small molecules, medical devices, and advanced therapies. Prior to his role at Elektrofi, Michael served as SVP of Cell Therapy Manufacturing at Nurix where he was Product Team Lead for cell therapy assets. Prior to Nurix, Michael was Global Head of Quality at Adaptimmune after spending 12 years working at Eli Lilly where his recent role was AVP Facilitities and Maintenance for Eli Lilly’s locations in New York and New Jersey.  Prior to Eli Lilly, Michael worked at Millennium Pharmaceuticals and Biomarin. Michael started his biotech career at IDEC Pharmaceuticals (Now Biogen) where he developed downstream processing methodologies for Rituxan.  Michael is active in the Parenteral Drug Association where he is a past Board Member and the immediate past chair and co-founder of the ATMP Advisory Board, co-founder of the ATMP Interest Group, a past member of the Biopharmaceutical Advisory Board, and co-contributor to several PDA Technical Reports dealing with lifecycle, steam in place, cell therapy, and oral solid dosage forms.